KPRX · Kiora Pharmaceuticals, Inc.

0001372514-26-000047

Summary

Operating losses widened 7.7% to -$2.5M in Q1 2026 amid clinical investments, with net cash burn accelerating to -$3.2M despite investing inflows from reduced security purchases and maturities.

Key takeaways

Net loss deepened 10.3% to -$2.4M versus -$2.2M prior year, driven by lower interest income from reduced rates, lower short-term security balances, and foreign currency losses.
Diluted EPS worsened 11.5% to -$0.58 from -$0.52, reflecting broader net loss expansion amid ongoing clinical development expenses.
Operating cash use rose to -$3.2M from -$2.7M, tied to higher net loss and working capital changes as the company funds R&D and operations.
Company expects continued significant expenses, increasing losses, and need for additional financing beyond late 2028 cash runway to reach commercialization.

Full analysis

Cash flow patterns reveal heightened operating demands, with net cash used in operating activities reaching -$3.2 million, up from -$2.7 million last year. This acceleration ties directly to the deeper net loss and shifts in working capital, as liquidity supports research, development, acquisitions, and capital expenditures—core historical needs. Free cash flow mirrored this at -$3.2 million after minimal $5 thousand in capital expenditures.